Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa
How UK biopharma must adapt to a changing landscape
But not as we know it?
Hopes the Moodivator app will complement treatment and support care teams
Promotes head of US Fertility and Endocrinology Craig Millian
Practical benefits for optimum patient outcomes
Sabrina Mogle will spearhead CRO’s US growth
Hopes to broaden reach of its Duchenne muscular dystrophy study
No two snowflakes or fingerprints are alike; the same is true of healthcare
Clinicians and commissioners are not usually health economists, so can we expect health economic models to be the only ones that resonate?